Intensified & Continuous Bioprocessing
Continuous Innovation. Intensified Results.
8/11/2026 - August 12, 2026 ALL TIMES EDT
Intensified and continuous bioprocessing is reshaping the economics and agility of modern biomanufacturing. This conference unites industry leaders, academics, and process engineers to explore the full continuum — from perfusion and intensified fed-batch upstream strategies to continuous downstream processing for mAbs, ADCs, and novel modalities. Sessions will also spotlight the digital technologies accelerating this transformation, including digital twins, AI-driven soft sensors, and real-time PAT tools enabling smarter, more integrated manufacturing platforms.
Preliminary Agenda

Session Block

INTENSIFIED UPSTREAM PROCESSING FOR NOVEL MODALITIES

KEYNOTE PRESENTATION: Intensified Fed-Batch and Continuous CHO Cell Cultures for Biologics Manufacturing

Photo of Weichang Zhou, PhD, CTO, MediLink Therapeutics , CTO , MediLink Therapeutics
Weichang Zhou, PhD, CTO, MediLink Therapeutics , CTO , MediLink Therapeutics

Innovative strategies are applied to enhance the productivity of fed-batch and continuous CHO cell cultures for biologics manufacturing. Raman spectroscopy, a real-time process analytical technology (PAT) tool, is utilized for process control. The ultra-intensified fed-batch platform, integrating N–1 perfusion and intermittent perfusion, increases productivity by 4–6 fold, while continuous perfusion cultures achieve significantly improved daily productivity through advanced cell lines, media, and process control.

Stable Perfusion Cultures of Mammalian Cells for Integrative Continuous Bioprocessing

Photo of Duk Jae Oh, PhD, Professor, Integrative Bioscience & Biotechnology, Sejong University , Prof , Integrative Bioscience & Biotechnology , Sejong University
Duk Jae Oh, PhD, Professor, Integrative Bioscience & Biotechnology, Sejong University , Prof , Integrative Bioscience & Biotechnology , Sejong University
Photo of Yuxin Liu, Senior Scientist, Sanofi Group , Sr Scientist , Sanofi Grp
Yuxin Liu, Senior Scientist, Sanofi Group , Sr Scientist , Sanofi Grp
Photo of Hussain Nuruddin Dahodwala, PhD, IBBR NIST-UMD , Professor , Upstream process development , IBBR-NIST
Hussain Nuruddin Dahodwala, PhD, IBBR NIST-UMD , Professor , Upstream process development , IBBR-NIST
Photo of Prashant Mainali, PhD, Scientist, Microbial Cell Bioprocessing, A STAR (Agency of Science, Technology and Research) , Scientist , Microbial Cell Bioprocessing , A STAR (Agency of Science, Technology and Research)
Prashant Mainali, PhD, Scientist, Microbial Cell Bioprocessing, A STAR (Agency of Science, Technology and Research) , Scientist , Microbial Cell Bioprocessing , A STAR (Agency of Science, Technology and Research)

Ana DiLillo, Assoc Specialist, Clinical Biologics, AstraZeneca , Assoc Specialist , Clinical Biologics , AstraZeneca

This talk explores strategies to optimize tangential flow filtration (TFF)–based perfusion systems to support efficient continuous biomanufacturing. It will highlight approaches to improve process productivity and streamline operations while reducing equipment demands and facility footprint.

CONTINUOUS AND INTENSIFIED DOWNSTREAM

FEATURED PRESENTATION: From Batches to Flow: Transforming Downstream Processing into a Continuous Enterprise

Photo of Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University , Prof & Head, Biotechnology , BOKU University , University of Natural Resources & Life Sciences
Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University , Prof & Head, Biotechnology , BOKU University , University of Natural Resources & Life Sciences

Continuous bioprocessing offers transformative potential but faces persistent scale-down and integration challenges. In downstream processing, maintaining stable micro- to milliliter-per-minute flow rates is essential, and fully continuous solid–liquid separation remains a bottleneck. Hollow-fiber based two-stage filtration provides a practical scale-down strategy, while continuous precipitation and flocculation represent powerful alternatives when robust separation is ensured. At manufacturing scale, fluid and buffer logistics dominate. Emerging soft-sensor concepts for online CQAs enable long-running, integrated processes, positioning continuous biomanufacturing as a cornerstone for future carbon-neutral pharmaceutical production.

Optimizing Throughput, Mass Indices, and Cost of Goods in Continuous, Precipitation-Based mAb Downstream Processing

Photo of Todd M. Przybycien, PhD, Professor and Head, Chemical and Biological Engineering, Rensselaer Polytechnic Institute , Professor and Head , Chemical & Biological Engineering , Rensselaer Polytechnic Institute
Todd M. Przybycien, PhD, Professor and Head, Chemical and Biological Engineering, Rensselaer Polytechnic Institute , Professor and Head , Chemical & Biological Engineering , Rensselaer Polytechnic Institute
Photo of Becky Chmielowski, PhD, Principal Scientist, Merck & Co. , Senior Principal Scientist , Merck & Co
Becky Chmielowski, PhD, Principal Scientist, Merck & Co. , Senior Principal Scientist , Merck & Co
Photo of Prakitr Srisuma, PhD, Postdoctoral Researcher, Chemical Engineering, MIT , Postdoctoral Researcher , Chemical Engineering , MIT
Prakitr Srisuma, PhD, Postdoctoral Researcher, Chemical Engineering, MIT , Postdoctoral Researcher , Chemical Engineering , MIT
Photo of Kurtis Denny, Engineer I, Cell Culture Development, Biogen , Sr. Engineer , Cell Culture Development , Biogen
Kurtis Denny, Engineer I, Cell Culture Development, Biogen , Sr. Engineer , Cell Culture Development , Biogen

A 785 nm Raman-based model was developed as an online measurement for the detergent concentration in a continuous viral inactivation (VI) step. In the VI step, detergent is continuously added to a concentrated bioreactor perfusate stream. The Raman flow cell was first calibrated using a bank of previously generated perfusate samples spiked to varying detergent levels to generate a PLS model with an estimated accuracy of 0.02% w/v.

INNOVATIONS IN FACILITY DESIGN, AI, AND AUTOMATION FOR CONTINUOUS/INTENSIFIED PROCESSES

Innovations for Next-Generation Biomanufacturing

Photo of Glen R. Bolton, PhD, Executive Director, Late Stage Bioprocess Development, Amgen, Inc. , AVP , Late Stage Bioprocess Development , Amgen Inc
Glen R. Bolton, PhD, Executive Director, Late Stage Bioprocess Development, Amgen, Inc. , AVP , Late Stage Bioprocess Development , Amgen Inc

How “Flexible” Platform Design Paradigm Enables Innovation to Support Highly Intensified-Processes

Jonathan K. Romero, PhD, Distinguished Scientist, BioProcess Research & Development, Merck Research Laboratories , Distinguished Scientist , BioProcess Research & Development , Merck Research Laboratories

Photo of Juergen Mairhofer, CEO & Co-Founder, enGenes Biotech GmbH , CEO & CoFounder , enGenes Biotech GmbH
Juergen Mairhofer, CEO & Co-Founder, enGenes Biotech GmbH , CEO & CoFounder , enGenes Biotech GmbH
Photo of William Whitford, Founder, Oamaru BioSystems , Founder , Oamaru BioSystems , Oamaru BioSystems
William Whitford, Founder, Oamaru BioSystems , Founder , Oamaru BioSystems , Oamaru BioSystems

A digital shadow is a near–real-time, data-driven virtual representation of a bioreactor and its process. An AI-augmented digital shadow (AIS) accelerates process intensification by integrating multivariate data with machine-learning and hybrid mechanistic models to identify actionable parameters and nonlinear interactions. AIS enables what-if simulation of equipment configurations, CPP strategies, and feeding profiles before execution. It can infer hard-to-measure state variables, assess scale equivalence, and support model-predictive and adaptive control by recommending near-optimal setpoints. By mapping high-dimensional parameter space and ranking limiting phenomena, AIS strengthens design-space definition, regulatory justification, first-time-right success, and manufacturing robustness.


For more details on the conference, please contact:

Mimi Langley

Executive Director, Conferences

Cambridge Healthtech Institute

Email: mlangley@healthtech.com

 

For sponsorship information, please contact:

 

Companies A-K

Phillip Zakim-Yacouby

Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-247-1815

Email: philzy@cambridgeinnovationinstitute.com

 

Companies L-Z

Aimee Croke

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-292-0777

Email: acroke@cambridgeinnovationinstitute.com